Lei Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lei Zhao has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- John Morser
Division of Hematology, Stanford University School of Medicine, Stanford, California, USA; Veterans Affairs Palo Alto Health Care System, Palo Alto, California, USA
7 shared publications - Lawrence L. K. Leung
Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305, USA
6 shared publications - Qin Zhou
Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305, USA
2 shared publications - Aishee B. Mukherji
Division of Primary Care and Population Health, Stanford University School of Medicine, Stanford, CA 94305, USA
1 shared publication - Anthony A. Fryer
School of Medicine, Keele University, Keele, UK
1 shared publication - Bettina Wanko
Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305, USA
1 shared publication
Latest Publications
- Open Access
- 18 April 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (4) , 991
Active Forms of Chemerin Are Elevated in Human and Mouse Ovarian Carcinoma
Background: Chemerin is a small adipokine that is activated and inactivated by proteolysis of its C-terminus with a role in regulating metabolism, immunity, and inflammation. Significant levels of chemerin are found in circulation and ascitic fluid of ovarian carcinoma patients. Methods: We investigated the levels of different chemerin forms in three cohorts: people with BMI < 25, with BMI > 40, and ovarian carcinoma ascites with ELISAs specific for different chemerin forms. Ascites from a mouse model of ovarian carcinoma were also analyzed, and the model was compared between wild-type and chemerin-deficient mice. Results: Conversion of plasma to serum increased the levels of processed chemerin with lower increases in samples from people with BMI < 25 than in people with BMI > 40. High levels of total chemerin and processed forms of chemerin were found in ascitic fluid from both patients who had a mean BMI of 29 and the mouse model. In chemerin-deficient mice the tumors grew slower than in wild-type mice. Conclusions: Serum has more processed and active chemerin than plasma irrespective of source. Ascites of ovarian carcinoma patients contained high levels of active chemerin, which, based on the mouse data, enhance tumor growth.
- 18 April 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (4) , 991
Open AccessActive Forms of Chemerin Are Elevated in Human and Mouse Ovarian Carcinoma
Background: Chemerin is a small adipokine that is activated and inactivated by proteolysis of its C-terminus with a role in regulating metabolism, immunity, and inflammation. Significant levels of chemerin are found in circulation and ascitic fluid of ovarian carcinoma patients. Methods: We investigated the levels of different chemerin forms in three cohorts: people with BMI < 25, with BMI > 40, and ovarian carcinoma ascites with ELISAs specific for different chemerin forms. Ascites from a mouse model of ovarian carcinoma were also analyzed, and the model was compared between wild-type and chemerin-deficient mice. Results: Conversion of plasma to serum increased the levels of processed chemerin with lower increases in samples from people with BMI < 25 than in people with BMI > 40. High levels of total chemerin and processed forms of chemerin were found in ascitic fluid from both patients who had a mean BMI of 29 and the mouse model. In chemerin-deficient mice the tumors grew slower than in wild-type mice. Conclusions: Serum has more processed and active chemerin than plasma irrespective of source. Ascites of ovarian carcinoma patients contained high levels of active chemerin, which, based on the mouse data, enhance tumor growth.
- Open Access
- 30 April 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (5) , 983
Chemerin Levels in Individuals with Type 2 Diabetes and a Normal Weight versus Individuals with Type 2 Diabetes and Obesity: An Observational, Cross-Sectional Study
Chemerin acts as both a chemotactic agent and an adipokine that undergoes proteolytic cleavage, converting inactive precursors into their active forms before being subsequently inactivated. Elevated chemerin levels are linked to obesity and type 2 diabetes mellitus (T2D). This study aimed to elucidate the effects of T2D and obesity on chemerin levels by comparing plasma samples from individuals with a normal weight and T2D (BMI < 25; NWD group n = 22) with those from individuals who are overweight or obese and have T2D (BMI ≥ 25; OWD group n = 39). The total chemerin levels were similar in the NWD and OWD groups, suggesting that T2D may equalize the chemerin levels irrespective of obesity status. The cleavage of chemerin has been previously linked to myocardial infarction and stroke in NWD, with potential implications for inflammation and mortality. OWD plasma exhibited lower levels of cleaved chemerin than the NWD group, suggesting less inflammation in the OWD group. Here, we showed that the interaction between obesity and T2D leads to an equalization in the total chemerin levels. The cleaved chemerin levels and the associated inflammatory state, however, differ significantly, underscoring the complex relationship between chemerin, T2D, and obesity.
- 30 April 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (5) , 983
Open AccessChemerin Levels in Individuals with Type 2 Diabetes and a Normal Weight versus Individuals with Type 2 Diabetes and Obesity: An Observational, Cross-Sectional Study
Chemerin acts as both a chemotactic agent and an adipokine that undergoes proteolytic cleavage, converting inactive precursors into their active forms before being subsequently inactivated. Elevated chemerin levels are linked to obesity and type 2 diabetes mellitus (T2D). This study aimed to elucidate the effects of T2D and obesity on chemerin levels by comparing plasma samples from individuals with a normal weight and T2D (BMI < 25; NWD group n = 22) with those from individuals who are overweight or obese and have T2D (BMI ≥ 25; OWD group n = 39). The total chemerin levels were similar in the NWD and OWD groups, suggesting that T2D may equalize the chemerin levels irrespective of obesity status. The cleavage of chemerin has been previously linked to myocardial infarction and stroke in NWD, with potential implications for inflammation and mortality. OWD plasma exhibited lower levels of cleaved chemerin than the NWD group, suggesting less inflammation in the OWD group. Here, we showed that the interaction between obesity and T2D leads to an equalization in the total chemerin levels. The cleaved chemerin levels and the associated inflammatory state, however, differ significantly, underscoring the complex relationship between chemerin, T2D, and obesity.
- Open Access
- 22 April 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (4) , 924
Chemerin in Participants with or without Insulin Resistance and Diabetes
Chemerin is a chemokine/adipokine, regulating inflammation, adipogenesis and energy metabolism whose activity depends on successive proteolytic cleavages at its C-terminus. Chemerin levels and processing are correlated with insulin resistance. We hypothesized that chemerin processing would be higher in individuals with type 2 diabetes (T2D) and in those who are insulin resistant (IR). This hypothesis was tested by characterizing different chemerin forms by specific ELISA in the plasma of 18 participants with T2D and 116 without T2D who also had their insulin resistance measured by steady-state plasma glucose (SSPG) concentration during an insulin suppression test. This approach enabled us to analyze the association of chemerin levels with a direct measure of insulin resistance (SSPG concentration). Participants were divided into groups based on their degree of insulin resistance using SSPG concentration tertiles: insulin sensitive (IS, SSPG ≤ 91 mg/dL), intermediate IR (IM, SSPG 92–199 mg/dL), and IR (SSPG ≥ 200 mg/dL). Levels of different chemerin forms were highest in patients with T2D, second highest in individuals without T2D who were IR, and lowest in persons without T2D who were IM or IS. In the whole group, chemerin levels positively correlated with both degree of insulin resistance (SSPG concentration) and adiposity (BMI). Participants with T2D and those without T2D who were IR had the most proteolytic processing of chemerin, resulting in higher levels of both cleaved and degraded chemerin. This suggests that increased inflammation in individuals who have T2D or are IR causes more chemerin processing.
- 22 April 2024
- Published by MDPI AG in Biomedicines
- Vol. 12 (4) , 924
Open AccessChemerin in Participants with or without Insulin Resistance and Diabetes
Chemerin is a chemokine/adipokine, regulating inflammation, adipogenesis and energy metabolism whose activity depends on successive proteolytic cleavages at its C-terminus. Chemerin levels and processing are correlated with insulin resistance. We hypothesized that chemerin processing would be higher in individuals with type 2 diabetes (T2D) and in those who are insulin resistant (IR). This hypothesis was tested by characterizing different chemerin forms by specific ELISA in the plasma of 18 participants with T2D and 116 without T2D who also had their insulin resistance measured by steady-state plasma glucose (SSPG) concentration during an insulin suppression test. This approach enabled us to analyze the association of chemerin levels with a direct measure of insulin resistance (SSPG concentration). Participants were divided into groups based on their degree of insulin resistance using SSPG concentration tertiles: insulin sensitive (IS, SSPG ≤ 91 mg/dL), intermediate IR (IM, SSPG 92–199 mg/dL), and IR (SSPG ≥ 200 mg/dL). Levels of different chemerin forms were highest in patients with T2D, second highest in individuals without T2D who were IR, and lowest in persons without T2D who were IM or IS. In the whole group, chemerin levels positively correlated with both degree of insulin resistance (SSPG concentration) and adiposity (BMI). Participants with T2D and those without T2D who were IR had the most proteolytic processing of chemerin, resulting in higher levels of both cleaved and degraded chemerin. This suggests that increased inflammation in individuals who have T2D or are IR causes more chemerin processing.
- Open Access
- 19 August 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (8) , 2018
Chemerin Forms: Their Generation and Activity
Chemerin is the product of the RARRES2 gene which is secreted as a precursor of 143 amino acids. That precursor is inactive, but proteases from the coagulation and fibrinolytic cascades, as well as from inflammatory reactions, process the C-terminus of chemerin to first activate it and then subsequently inactivate it. Chemerin can signal via two G protein-coupled receptors, chem1 and chem2, as well as be bound to a third non-signaling receptor, CCRL2. Chemerin is produced by the liver and secreted into the circulation as a precursor, but it is also expressed in some tissues where it can be activated locally. This review discusses the specific tissue expression of the components of the chemerin system, and the role of different proteases in regulating the activation and inactivation of chemerin. Methods of identifying and determining the levels of different chemerin forms in both mass and activity assays are reviewed. The levels of chemerin in circulation are correlated with certain disease conditions, such as patients with obesity or diabetes, leading to the possibility of using chemerin as a biomarker.
- 19 August 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (8) , 2018
Open AccessChemerin Forms: Their Generation and Activity
Chemerin is the product of the RARRES2 gene which is secreted as a precursor of 143 amino acids. That precursor is inactive, but proteases from the coagulation and fibrinolytic cascades, as well as from inflammatory reactions, process the C-terminus of chemerin to first activate it and then subsequently inactivate it. Chemerin can signal via two G protein-coupled receptors, chem1 and chem2, as well as be bound to a third non-signaling receptor, CCRL2. Chemerin is produced by the liver and secreted into the circulation as a precursor, but it is also expressed in some tissues where it can be activated locally. This review discusses the specific tissue expression of the components of the chemerin system, and the role of different proteases in regulating the activation and inactivation of chemerin. Methods of identifying and determining the levels of different chemerin forms in both mass and activity assays are reviewed. The levels of chemerin in circulation are correlated with certain disease conditions, such as patients with obesity or diabetes, leading to the possibility of using chemerin as a biomarker.
- 16 February 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (5) , 1256-1270
Thrombin cleavage of osteopontin initiates osteopontin’s tumor‐promoting activity
- 16 February 2022
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (5) , 1256-1270
Thrombin cleavage of osteopontin initiates osteopontin’s tumor‐promoting activity
- 9 October 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (1) , 238-244
Both plasma basic carboxypeptidases, carboxypeptidase B2 and carboxypeptidase N, regulate vascular leakage activity in mice
- 9 October 2021
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 20 (1) , 238-244
Both plasma basic carboxypeptidases, carboxypeptidase B2 and carboxypeptidase N, regulate vascular leakage activity in mice
- 16 June 2020
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 117 (10) , 2923-2932
Spy chemistry‐enabled protein directional immobilization and protein purification
Site‐directed protein immobilization allows the homogeneous orientation of proteins with high retention of activity, which is advantageous for many applications. Here, we report a facile, specific, and efficient strategy based on the SpyTag‐SpyCatcher chemistry. Two SpyTag‐fused model proteins, that is, the monomeric red fluorescent protein (RFP) and the oligomeric glutaryl‐7‐aminocephalosporanic acid acylase, were easily immobilized onto a SpyCatcher‐modified resin directly from cell lysates, with activity recoveries in the range of 85–91%. This strategy was further adapted to protein purification, which proceeded through the selective capture of the SpyCatcher‐fused target proteins by a SpyTag‐modified resin, with the aid of an intein to generate authentic N‐termini. For two model proteins, that is, RFP and a variable domain of a heavy chain antibody, the yields were ∼3–7 mg/L culture with >90% purities. This approach could provide a versatile tool for producing high‐performance immobilized protein devices and proteins for industrial and therapeutic uses.
- 16 June 2020
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 117 (10) , 2923-2932
Spy chemistry‐enabled protein directional immobilization and protein purification
Site‐directed protein immobilization allows the homogeneous orientation of proteins with high retention of activity, which is advantageous for many applications. Here, we report a facile, specific, and efficient strategy based on the SpyTag‐SpyCatcher chemistry. Two SpyTag‐fused model proteins, that is, the monomeric red fluorescent protein (RFP) and the oligomeric glutaryl‐7‐aminocephalosporanic acid acylase, were easily immobilized onto a SpyCatcher‐modified resin directly from cell lysates, with activity recoveries in the range of 85–91%. This strategy was further adapted to protein purification, which proceeded through the selective capture of the SpyCatcher‐fused target proteins by a SpyTag‐modified resin, with the aid of an intein to generate authentic N‐termini. For two model proteins, that is, RFP and a variable domain of a heavy chain antibody, the yields were ∼3–7 mg/L culture with >90% purities. This approach could provide a versatile tool for producing high‐performance immobilized protein devices and proteins for industrial and therapeutic uses.
- Open Access
- 4 July 2018
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 20 (1) , 1-9
Chemerin 156F, generated by chymase cleavage of prochemerin, is elevated in joint fluids of arthritis patients
Chemerin is a chemoattractant involved in immunity that also functions as an adipokine. Chemerin is secreted as an inactive precursor (chem163S), and its activation requires proteolytic cleavages at its C-terminus, involving proteases in coagulation, fibrinolysis, and inflammation. Previously, we found chem158K was the dominant chemerin form in synovial fluids from patients with arthritis. In this study, we aimed to characterize a distinct cleaved chemerin form, chem156F, in osteoarthritis (OA) and rheumatoid arthritis (RA). Purified chem156F was produced in transfected CHO cells. To quantify chem156F in OA and RA samples, we developed a specific ELISA for chem156F using antibody raised against a peptide representing the C-terminus of chem156F. Ca2+ mobilization assays showed that the EC50 values for chem163S, chem156F, and chem157S were 252 ± 141 nM, 133 ± 41.5 nM, and 5.83 ± 2.48 nM, respectively. chem156F was more active than its precursor, chem163S, but very much less potent than chem157S, the most active chemerin form. Chymase was shown to be capable of cleaving chem163S at a relevant rate. Using the chem156F ELISA we found a substantial amount of chem156F present in synovial fluids from patients with OA and RA, 24.06 ± 5.51 ng/ml and 20.35 ± 5.19 ng/ml (mean ± SEM, n = 25) respectively, representing 20% of total chemerin in OA and 76.7% of chemerin in RA synovial fluids. Our data show that chymase cleavage of chem163S to partially active chem156F can be found in synovial fluids where it can play a role in modulation of the inflammation in joints.
- 4 July 2018
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 20 (1) , 1-9
Open AccessChemerin 156F, generated by chymase cleavage of prochemerin, is elevated in joint fluids of arthritis patients
Chemerin is a chemoattractant involved in immunity that also functions as an adipokine. Chemerin is secreted as an inactive precursor (chem163S), and its activation requires proteolytic cleavages at its C-terminus, involving proteases in coagulation, fibrinolysis, and inflammation. Previously, we found chem158K was the dominant chemerin form in synovial fluids from patients with arthritis. In this study, we aimed to characterize a distinct cleaved chemerin form, chem156F, in osteoarthritis (OA) and rheumatoid arthritis (RA). Purified chem156F was produced in transfected CHO cells. To quantify chem156F in OA and RA samples, we developed a specific ELISA for chem156F using antibody raised against a peptide representing the C-terminus of chem156F. Ca2+ mobilization assays showed that the EC50 values for chem163S, chem156F, and chem157S were 252 ± 141 nM, 133 ± 41.5 nM, and 5.83 ± 2.48 nM, respectively. chem156F was more active than its precursor, chem163S, but very much less potent than chem157S, the most active chemerin form. Chymase was shown to be capable of cleaving chem163S at a relevant rate. Using the chem156F ELISA we found a substantial amount of chem156F present in synovial fluids from patients with OA and RA, 24.06 ± 5.51 ng/ml and 20.35 ± 5.19 ng/ml (mean ± SEM, n = 25) respectively, representing 20% of total chemerin in OA and 76.7% of chemerin in RA synovial fluids. Our data show that chymase cleavage of chem163S to partially active chem156F can be found in synovial fluids where it can play a role in modulation of the inflammation in joints.
- 1 January 1993
- Published by Taylor & Francis in Free Radical Research Communications
- Vol. 19 (3) , 159-171
Alpha, Mu and Pi Class Glutathione S-Transferases in Human Synovium and Cultured Synovial Fibroblasts: Effects of Interleukin-1α, Hydrogen Peroxide and Inhibition of Eicosanoid Synthesis
We describe expression of alpha, mu and pi class glutathione S-transferase (GST) and, CuZn- and Mn superoxide dismutase (SOD) in human synovium and cultured synovial fibroblasts. Immunohistochemical and immunoblotting studies showed synovium and cultured cells expressed pi GST and both isoforms of SOD. Cellular localisation was largely perinuclear. No expression of alpha or mu GST was detected even though polymerase chain reaction analysis showed 4/6 subjects had positive genotypes at the polymorphic, mu class GSTM1 locus. Incubation of cultured synovial fibroblasts with H2O2, IL-1 alpha and the cyclooxygenase and lipoxygenase inhibitor, Tenidap, did not induce expression of alpha, mu or pi GST though treatment with IL-1 alpha caused a marked increase in the expression of Mn SOD.
- 1 January 1993
- Published by Taylor & Francis in Free Radical Research Communications
- Vol. 19 (3) , 159-171
Alpha, Mu and Pi Class Glutathione S-Transferases in Human Synovium and Cultured Synovial Fibroblasts: Effects of Interleukin-1α, Hydrogen Peroxide and Inhibition of Eicosanoid Synthesis
We describe expression of alpha, mu and pi class glutathione S-transferase (GST) and, CuZn- and Mn superoxide dismutase (SOD) in human synovium and cultured synovial fibroblasts. Immunohistochemical and immunoblotting studies showed synovium and cultured cells expressed pi GST and both isoforms of SOD. Cellular localisation was largely perinuclear. No expression of alpha or mu GST was detected even though polymerase chain reaction analysis showed 4/6 subjects had positive genotypes at the polymorphic, mu class GSTM1 locus. Incubation of cultured synovial fibroblasts with H2O2, IL-1 alpha and the cyclooxygenase and lipoxygenase inhibitor, Tenidap, did not induce expression of alpha, mu or pi GST though treatment with IL-1 alpha caused a marked increase in the expression of Mn SOD.